Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 13 Mar 2023
When an elderly boater falls into shallow water, an emergency medical attendant leaves the boat and goes to work.
Read Full NewsThe phase 3 HARMONIA trial will evaluate whether a muscle- and CNS-targeted antisense conjugate improves function across multiple systems in patients with myotonic dystrophy type 1.
New data from the 2026 AANEM Annual Meeting showed zilucoplan delivered via autoinjector was bioequivalent to the pre-filled syringe and was well tolerated when self-administered by patients with generalized myasthenia gravis.
The ongoing phase 3 study is enrolling approximately 180 adults across more than 13 countries, with topline results expected in mid-2027.
EpilepsyGTx and Viralgen have entered a manufacturing collaboration to support development of EPY201, an investigational AAV9-based gene therapy for focal refractory epilepsy planned to enter first-in-human testing in 2027.
Phase 3 trials EMNERGIZE and EMVIGORATE will evaluate the efficacy and safety of intravenous empasiprubart in adults with chronic inflammatory demyelinating polyradiculoneuropathy.
The chairman of the Neurology Service Line at Baptist Health in Kentucky discussed PREVIEW trial findings for gefelorilimab in generalized myasthenia gravis, including efficacy, safety, and what the subcutaneous C5 inhibitor could offer patients if approved.
Lessons From 10,000 Organ Transplants, With Ari Cohen, MD
1.
Researchers use genomic technology to investigate aggressive skin cancer linked to burn scars
2.
PSMA-PET/CT Detects Metastatic Prostate Cancer Missed by Other Imaging
3.
COVID Lockdowns Significantly Increasing Children's Vitamin D Deficiency?
4.
Researchers identify a novel biomarker linked to renal cancer recurrence
5.
Canadian Group Calls for Earlier Colorectal Cancer Screening
1.
Chronic Cancer Survivorship: Managing Long-Term Outcomes with Precision Care
2.
Innovative Directions in Hematology Across Clinical Settings
3.
Understanding Mean Corpuscular Volume: A Comprehensive Guide
4.
Structural Variant Landscapes in Solid Tumors: Clinical and Molecular Perspectives
5.
How HLH is Revolutionizing Healthcare
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Thromboprophylaxis In Medical Settings
3.
Current Scenario of Blood Cancer- Genomic Testing & Advancement in Diagnosis and Treatment
4.
CDK4/6 Inhibitors Redefining Treatment for HR+/HER2- aBC In Post-Menopausal Women- A Panel Discussion
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge